Linnaeus Venture is proud to announce a new strategic partnership and investment in the innovative startup Core-Oli-T AB. Through this investment and collaboration, we are taking an active step toward enabling the company’s next growth phase – with a strong focus on creating long-term value.
Core-Oli-T is a research-based company with roots at Linnaeus University. Their groundbreaking scientific discoveries have the potential to enable early precision diagnostics for Parkinson’s disease and, in the long run, offer an effective treatment method to halt disease progression. This is based on the company’s breakthrough in unique antibody technology.
The company’s founders, Associate Professor of Physical Chemistry Björn C.G. Karlsson and Dr. Thomas Näsström, hold deep expertise in the field. Björn brings specialized knowledge in the development of synthetic antibodies for diagnostic applications, while Thomas has extensive experience in developing antibodies targeting neurodegenerative diseases such as Parkinson’s.
“Core-Oli-T’s pioneering research aligns perfectly with our mission to support innovations that have the potential to address major societal challenges. We look forward to this collaboration and the opportunity to make a real difference – both for people living with Parkinson’s disease and for society as a whole”,
says Evelina Mikaelson, CEO Linnaeus Venture.
Image: Björn C.G Karlsson & Thomas Näsström
